Literature DB >> 25776482

Expression of MicroRNA-325-3p and its potential functions by targeting HMGB1 in non-small cell lung cancer.

Shihua Yao1, Tiejun Zhao1, Hai Jin2.   

Abstract

MicroRNAs (miRNAs) can function as tumor suppressors and might provide an efficient strategy for annihilating cancer. Nevertheless, the potential role of miR-325-3p in NSCLC is still unknown. Here, we showed that miR-325-3p was decreased and HMGB1 was increased in 107 NSCLC patients. MiR-325-3p inhibition promoted cell invasion and proliferation, while miR-325-3p upregulation inhibited cell invasion and proliferation by using transwell and CCK8 assays. Using a bioinformatics method, we further showed that HMGB1 might be a direct target of miR-325-3p and is negatively regulated by miR-325-3p. Down-regulation of miR-325-3p predicts poor prognosis for NSCLC patients. These findings implied that miR-325-3p regulates cell invasion and proliferation via targeting HMGB1 and may be a potential prognostic marker for NSCLC.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  HMGB1; Invasion; NSCLC; Prognosis; Proliferation; miR-325-3p

Mesh:

Substances:

Year:  2015        PMID: 25776482     DOI: 10.1016/j.biopha.2015.01.013

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  18 in total

1.  Unique microRNA Signals in Plasma Exosomes from Pregnancies Complicated by Preeclampsia.

Authors:  Hui Li; Yingshi Ouyang; Elena Sadovsky; W Tony Parks; Tianjiao Chu; Yoel Sadovsky
Journal:  Hypertension       Date:  2020-01-27       Impact factor: 10.190

2.  Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.

Authors:  Ruiguang Zhang; Yan Li; Zhongliang Wang; Lingjuan Chen; Xiaorong Dong; Xiu Nie
Journal:  Tumour Biol       Date:  2015-06-04

3.  MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.

Authors:  Yun Liu; Xu Hu; Daokui Xia; Songlin Zhang
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

Review 4.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

5.  Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells.

Authors:  Karthik Subramanian Chandrasekaran; Anusha Sathyanarayanan; Devarajan Karunagaran
Journal:  Tumour Biol       Date:  2016-07-25

6.  MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.

Authors:  Li Zhang; Heping Chen; Yueqiong Song; Qing Gu; Lu Zhang; Qin Xie; Jin Xu; Min Zhang
Journal:  Dig Dis Sci       Date:  2020-09-10       Impact factor: 3.199

7.  LncARSR promotes non-small-cell lung cancer progression via regulating PTEN/Akt.

Authors:  Jie Ying; Jian Yang; Yingzi Liu
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

8.  A Causal Relationship in Spinal Cord Injury Rat Model Between Microglia Activation and EGFR/MAPK Detected by Overexpression of MicroRNA-325-3p.

Authors:  Penghui Yan; Xuejian Wu; Xiaokang Liu; Yingchun Cai; Chenglong Shao; Guangduo Zhu
Journal:  J Mol Neurosci       Date:  2019-03-25       Impact factor: 3.444

Review 9.  HMGB1 as a therapeutic target in disease.

Authors:  Jiaming Xue; Joelle S Suarez; Michael Minaai; Shuangjing Li; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  J Cell Physiol       Date:  2020-10-26       Impact factor: 6.384

10.  miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.

Authors:  Ovidiu-Leonard Braicu; Liviuta Budisan; Rares Buiga; Ancuta Jurj; Patriciu Achimas-Cadariu; Laura Ancuta Pop; Cornelia Braicu; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Onco Targets Ther       Date:  2017-08-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.